Evangeline Ifeoma Emesue, MD | |
2401 Park Dr Ste 101, Harrisburg, PA 17110-9303 | |
(717) 686-9842 | |
Not Available |
Full Name | Evangeline Ifeoma Emesue |
---|---|
Gender | Female |
Speciality | Internal Medicine |
Location | 2401 Park Dr Ste 101, Harrisburg, Pennsylvania |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1033553540 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207R00000X | Internal Medicine | MD459402 (Pennsylvania) | Primary |
Entity Name | Pinnacle Health Medical Services |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1932143427 PECOS PAC ID: 7618960493 Enrollment ID: O20040407000180 |
News Archive
A comprehensive review into what we know about COVID-19 and the way it functions suggests the virus has a unique infectious profile, which explains why it can be so hard to treat and why some people experience so-called "long-COVID", struggling with significant health issues months after infection.
Prenatal exposure to selective serotonin reuptake inhibitors, especially during the first trimester, is associated with a modest increase the risk of developing an autism spectrum disorder, according to a report published Online First in the Archives of General Psychiatry, one of the JAMA/Archives journals.
A multidisciplinary team led by a geneticist and psychiatrist from Cold Spring Harbor Laboratory's (CSHL) Stanley Institute for Cognitive Genomics today publish a paper providing a glimpse of both the tremendous power and the current limitations of what is sometimes called "precision medicine."
ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.
The PETA International Science Consortium's nanotechnology expert will present a poster titled "A Tiered-Testing Strategy for Nanomaterial Hazard Assessment" at the Topical Scientific Workshop – Regulatory Challenges in Risk Assessment of Nanomaterials being organized by the European Chemicals Agency (ECHA) on October 23 and 24 in Helsinki.
› Verified 4 days ago
Entity Name | Clearfield-jefferson Primary Care Associates Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1710233895 PECOS PAC ID: 6002064433 Enrollment ID: O20120910000652 |
News Archive
A comprehensive review into what we know about COVID-19 and the way it functions suggests the virus has a unique infectious profile, which explains why it can be so hard to treat and why some people experience so-called "long-COVID", struggling with significant health issues months after infection.
Prenatal exposure to selective serotonin reuptake inhibitors, especially during the first trimester, is associated with a modest increase the risk of developing an autism spectrum disorder, according to a report published Online First in the Archives of General Psychiatry, one of the JAMA/Archives journals.
A multidisciplinary team led by a geneticist and psychiatrist from Cold Spring Harbor Laboratory's (CSHL) Stanley Institute for Cognitive Genomics today publish a paper providing a glimpse of both the tremendous power and the current limitations of what is sometimes called "precision medicine."
ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.
The PETA International Science Consortium's nanotechnology expert will present a poster titled "A Tiered-Testing Strategy for Nanomaterial Hazard Assessment" at the Topical Scientific Workshop – Regulatory Challenges in Risk Assessment of Nanomaterials being organized by the European Chemicals Agency (ECHA) on October 23 and 24 in Helsinki.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Evangeline Ifeoma Emesue, MD 6 Market Plaza Way, Mechanicsburg, PA 17055-5659 Ph: (717) 766-0228 | Evangeline Ifeoma Emesue, MD 2401 Park Dr Ste 101, Harrisburg, PA 17110-9303 Ph: (717) 686-9842 |
News Archive
A comprehensive review into what we know about COVID-19 and the way it functions suggests the virus has a unique infectious profile, which explains why it can be so hard to treat and why some people experience so-called "long-COVID", struggling with significant health issues months after infection.
Prenatal exposure to selective serotonin reuptake inhibitors, especially during the first trimester, is associated with a modest increase the risk of developing an autism spectrum disorder, according to a report published Online First in the Archives of General Psychiatry, one of the JAMA/Archives journals.
A multidisciplinary team led by a geneticist and psychiatrist from Cold Spring Harbor Laboratory's (CSHL) Stanley Institute for Cognitive Genomics today publish a paper providing a glimpse of both the tremendous power and the current limitations of what is sometimes called "precision medicine."
ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.
The PETA International Science Consortium's nanotechnology expert will present a poster titled "A Tiered-Testing Strategy for Nanomaterial Hazard Assessment" at the Topical Scientific Workshop – Regulatory Challenges in Risk Assessment of Nanomaterials being organized by the European Chemicals Agency (ECHA) on October 23 and 24 in Helsinki.
› Verified 4 days ago
Lindsey Marie Govern, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 810 Sir Thomas Ct Ste 101, Harrisburg, PA 17109 Phone: 717-614-4420 Fax: 717-614-4421 | |
Quan Tran, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 111 S Front St, Harrisburg, PA 17101 Phone: 717-231-8772 | |
Richard Haley Jeffries, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4830 Londonderry Rd, Harrisburg, PA 17109 Phone: 717-657-2595 Fax: 717-657-3091 | |
Joanne G Gordon, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 111 S Front St, Harrisburg, PA 17101 Phone: 717-782-3380 Fax: 717-782-5716 | |
Dr. David Edward Dudick, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 111 S Front St, Internal Medicine Residency Program, Brady Hall 3, Harrisburg, PA 17101 Phone: 717-782-3131 | |
Emily Ramasra, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 111 S Front St, Harrisburg, PA 17101 Phone: 717-231-8506 | |
Mr. Siddharth Goel, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 205 S Front St Upmc Pinnacle, Internal Medicine Residen, Suite 3c, Harrisburg, PA 17104 Phone: 717-231-8506 Fax: 717-231-8535 |